Summary Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as extracutaneous melanoma. It is the deadliest form of skin cancer and remains one of the most aggressive and treatmentresistant human cancers.
Global prevalence of the disease has risen significantly in the past several decades, primarily due to an increase in exposure to UV light and / or sunlight. This has resulted in an increase in developmental interest with regard to improving disease management, particularly in the advanced metastatic setting.
The emergence over the past decade of novel targeted therapies and therapies that manipulate the immune response has improved treatment options for patients. These new drug classes have been highly commercially successful with blockbuster products that are now well established within the treatment algorithm.
In spite of these developments, there are still significant unmet needs for both cutaneous and extracutaneous melanoma, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the melanoma pipeline, which is substantially larger than the current market.
Request a sample of this report @ http:// www. orbisresearch. com / contacts / requestsample / 193024.
Scope Rising global prevalence and unmet need have resulted in an increase in developmental interest- What is the pathophysiology of melanoma?- How has the emergence of new drug classes in the past decade impacted the treatment algorithm?- What are the most significant unmet needs within the market? The melanoma pipeline is large and innovative in comparison with the current market- Which molecule types and molecular targets are most prominent within the pipeline?- Which first-in-class targets are most promising?- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?- Do melanoma products attract high deal values?- Which molecule types and molecular targets dominate the deals landscape?- Which first-in-class pipeline products have no prior involvement in licensing or codevelopment deals?
2